Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

LDL-C Assessment w/ PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2 (LAPLACE-2)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Amgen
ClinicalTrials.gov Identifier:
NCT01763866
First received: January 7, 2013
Last updated: July 8, 2014
Last verified: July 2014
  Purpose

The primary hypothesis is that both dosing regimens of evolocumab (AMG 145) subcutaneous will be well tolerated and will result in greater reduction of Low Density Lipoprotein-Cholesterol in subjects with primary hypercholesterolemia and mixed dyslipidemia.


Condition Intervention Phase
Hyperlipidemia
Biological: evolocumab (AMG 145)
Other: Ezetimibe
Other: Placebo (administered subcutaneously)
Other: Placebo (administered orally)
Drug: Atorvastatin
Drug: Rosuvastatin
Drug: Simvastatin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-blind, Randomized, Placebo and Ezetimibe Controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 on LDL-C in Combination With Statin Therapy in Subjects With Primary Hypercholesterolemia and Mixed Dyslipidemia

Resource links provided by NLM:


Further study details as provided by Amgen:

Primary Outcome Measures:
  • Mean percent change from baseline in low density lipoprotein-cholesterol [ Time Frame: 10 and 12 Weeks ] [ Designated as safety issue: No ]
    Mean percent change from baseline in low density lipoprotein-cholesterol

  • Percent change from baseline in low density lipoprotein-cholesterol [ Time Frame: 12 Weeks ] [ Designated as safety issue: No ]
    Percent change from baseline in low density lipoprotein-cholesterol


Secondary Outcome Measures:
  • Mean change from baseline in low density lipoprotein-cholesterol [ Time Frame: 10 and 12 Weeks ] [ Designated as safety issue: No ]
    Mean change from baseline in low density lipoprotein-cholesterol

  • Change from baseline in low density lipoprotein-cholesterol [ Time Frame: 12 Weeks ] [ Designated as safety issue: No ]
    Change from baseline in low density lipoprotein-cholesterol

  • Mean percent change from baseline in non-high density lipoprotein-cholesterol [ Time Frame: 10 and 12 Weeks ] [ Designated as safety issue: No ]
    Mean percent change from baseline in non-high density lipoprotein-cholesterol

  • Percent change from baseline in non-high density lipoprotein-cholesterol [ Time Frame: 12 Weeks ] [ Designated as safety issue: No ]
    Percent change from baseline in non-high density lipoprotein-cholesterol

  • Mean percent change from baseline in apolipoprotein B [ Time Frame: 10 and 12 Weeks ] [ Designated as safety issue: No ]
    Mean percent change from baseline in apolipoprotein B

  • Percent change from baseline in apolipoprotein B [ Time Frame: 12 Weeks ] [ Designated as safety issue: No ]
    Percent change from baseline in apolipoprotein B

  • Mean percent change from baseline in the total cholesterol/high density lipoprotein-cholesterol ratio [ Time Frame: 10 and 12 Weeks ] [ Designated as safety issue: No ]
    Mean percent change from baseline in the total cholesterol/high density lipoprotein-cholesterol ratio

  • Percent change from baseline in the total cholesterol/high density lipoprotein-cholesterol ratio [ Time Frame: 12 Weeks ] [ Designated as safety issue: No ]
    Percent change from baseline in the total cholesterol/high density lipoprotein-cholesterol ratio

  • Mean percent change from baseline in apolipoprotein B/apolipoprotein A1 ratio [ Time Frame: 10 and 12 Weeks ] [ Designated as safety issue: No ]
    Mean percent change from baseline in apolipoprotein B/apolipoprotein A1 ratio

  • Percent change from baseline in apolipoprotein B/apolipoprotein A1 ratio [ Time Frame: 12 Weeks ] [ Designated as safety issue: No ]
    Percent change from baseline in apolipoprotein B/apolipoprotein A1 ratio

  • Mean low density lipoprotein-cholesterol response (low density lipoprotein-cholesterol < 70 mg/dL [1.8 mmol/L]) [ Time Frame: 10 and 12 Weeks ] [ Designated as safety issue: No ]
    Mean low density lipoprotein-cholesterol response (low density lipoprotein-cholesterol < 70 mg/dL [1.8 mmol/L])

  • Low density lipoprotein-cholesterol response (low density lipoprotein-cholesterol < 70 mg/dL [1.8 mmol/L]) [ Time Frame: 12 Weeks ] [ Designated as safety issue: No ]
    Low density lipoprotein-cholesterol response (low density lipoprotein-cholesterol < 70 mg/dL [1.8 mmol/L])

  • Mean percent change from baseline in lipoprotein (a) [ Time Frame: 10 and 12 Weeks ] [ Designated as safety issue: No ]
    Mean percent change from baseline in lipoprotein (a)

  • Percent change from baseline in lipoprotein (a) [ Time Frame: 12 Weeks ] [ Designated as safety issue: No ]
    Percent change from baseline in lipoprotein (a)

  • Mean percent change from baseline in triglycerides [ Time Frame: 10 and 12 Weeks ] [ Designated as safety issue: No ]
    Mean percent change from baseline in triglycerides

  • Percent change from baseline in triglycerides [ Time Frame: 12 Weeks ] [ Designated as safety issue: No ]
    Percent change from baseline in triglycerides

  • Mean percent change from baseline in high density lipoprotein-cholesterol [ Time Frame: 10 and 12 Weeks ] [ Designated as safety issue: No ]
    Mean percent change from baseline in high density lipoprotein-cholesterol

  • Percent change from baseline in high density lipoprotein-cholesterol [ Time Frame: 12 Weeks ] [ Designated as safety issue: No ]
    Percent change from baseline in high density lipoprotein-cholesterol

  • Mean percent change from baseline in very low-density lipoprotein cholesterol [ Time Frame: 10 and 12 Weeks ] [ Designated as safety issue: No ]
    Mean percent change from baseline in very low-density lipoprotein cholesterol

  • Percent change from baseline in very low-density lipoprotein cholesterol [ Time Frame: 12 Weeks ] [ Designated as safety issue: No ]
    Percent change from baseline in very low-density lipoprotein cholesterol


Enrollment: 1896
Study Start Date: January 2013
Study Completion Date: January 2014
Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Arm 1
Dose 1 of statin therapy and placebo orally/daily and placebo subcutaneously every 2 weeks
Other: Placebo (administered subcutaneously)
Subject will receive Placebo every 2 weeks or monthly. All subjects at screening will participate in the placebo run-in.
Other: Placebo (administered orally)
Subject will receive Placebo daily
Drug: Atorvastatin
Subject will receive statin therapy daily
Placebo Comparator: Arm 2
Dose 2 of statin therapy and placebo orally/daily and placebo subcutaneously monthly
Other: Placebo (administered subcutaneously)
Subject will receive Placebo every 2 weeks or monthly. All subjects at screening will participate in the placebo run-in.
Other: Placebo (administered orally)
Subject will receive Placebo daily
Drug: Atorvastatin
Subject will receive statin therapy daily
Arm 3
Dose 3 of statin therapy and Ezetimibe orally/daily and placebo subcutaneously every 2 weeks
Other: Ezetimibe
Subject will receive Ezetimibe daily
Other: Placebo (administered subcutaneously)
Subject will receive Placebo every 2 weeks or monthly. All subjects at screening will participate in the placebo run-in.
Drug: Atorvastatin
Subject will receive statin therapy daily
Arm 4
Dose 4 of statin therapy and Ezetimibe orally/daily and placebo subcutaneously monthly
Other: Ezetimibe
Subject will receive Ezetimibe daily
Other: Placebo (administered subcutaneously)
Subject will receive Placebo every 2 weeks or monthly. All subjects at screening will participate in the placebo run-in.
Drug: Atorvastatin
Subject will receive statin therapy daily
Active Comparator: Arm 5
Dose 5 of statin therapy and placebo orally/daily and evolocumab (AMG 145) subcutaneously every 2 weeks
Biological: evolocumab (AMG 145)
Subject will receive evolocumab (AMG 145) every 2 weeks or monthly
Other: Placebo (administered orally)
Subject will receive Placebo daily
Drug: Atorvastatin
Subject will receive statin therapy daily
Active Comparator: Arm 6
Dose 6 of statin therapy and placebo orally/daily and evolocumab (AMG 145) subcutaneously monthly
Biological: evolocumab (AMG 145)
Subject will receive evolocumab (AMG 145) every 2 weeks or monthly
Other: Placebo (administered orally)
Subject will receive Placebo daily
Drug: Atorvastatin
Subject will receive statin therapy daily
Placebo Comparator: Arm 7
Dose 7 of statin therapy and placebo orally/daily and placebo subcutaneously every 2 weeks
Other: Placebo (administered subcutaneously)
Subject will receive Placebo every 2 weeks or monthly. All subjects at screening will participate in the placebo run-in.
Other: Placebo (administered orally)
Subject will receive Placebo daily
Drug: Atorvastatin
Subject will receive statin therapy daily
Placebo Comparator: Arm 8
Dose 8 of statin therapy and placebo orally/daily and placebo subcutaneously monthly
Other: Placebo (administered subcutaneously)
Subject will receive Placebo every 2 weeks or monthly. All subjects at screening will participate in the placebo run-in.
Other: Placebo (administered orally)
Subject will receive Placebo daily
Drug: Atorvastatin
Subject will receive statin therapy daily
Arm 9
Dose 9 of statin therapy and Ezetimibe orally/daily and placebo subcutaneously every 2 weeks
Other: Ezetimibe
Subject will receive Ezetimibe daily
Other: Placebo (administered subcutaneously)
Subject will receive Placebo every 2 weeks or monthly. All subjects at screening will participate in the placebo run-in.
Drug: Atorvastatin
Subject will receive statin therapy daily
Arm 10
Dose 10 of statin therapy and Ezetimibe orally/daily and placebo subcutaneously monthly
Other: Ezetimibe
Subject will receive Ezetimibe daily
Other: Placebo (administered subcutaneously)
Subject will receive Placebo every 2 weeks or monthly. All subjects at screening will participate in the placebo run-in.
Drug: Atorvastatin
Subject will receive statin therapy daily
Active Comparator: Arm 11
Dose 11 of statin therapy and placebo orally/daily and evolocumab (AMG 145) subcutaneously every 2 weeks
Biological: evolocumab (AMG 145)
Subject will receive evolocumab (AMG 145) every 2 weeks or monthly
Other: Placebo (administered orally)
Subject will receive Placebo daily
Drug: Atorvastatin
Subject will receive statin therapy daily
Active Comparator: Arm 12
Dose 12 of statin therapy and placebo orally/daily and evolocumab (AMG 145) subcutaneously monthly
Biological: evolocumab (AMG 145)
Subject will receive evolocumab (AMG 145) every 2 weeks or monthly
Other: Placebo (administered orally)
Subject will receive Placebo daily
Drug: Atorvastatin
Subject will receive statin therapy daily
Placebo Comparator: Arm 13
Dose 13 of statin therapy orally/daily and placebo subcutaneously every 2 weeks
Other: Placebo (administered subcutaneously)
Subject will receive Placebo every 2 weeks or monthly. All subjects at screening will participate in the placebo run-in.
Drug: Rosuvastatin
Subject will receive statin therapy daily
Placebo Comparator: Arm 14
Dose 14 of statin therapy orally/daily and placebo subcutaneously monthly
Other: Placebo (administered subcutaneously)
Subject will receive Placebo every 2 weeks or monthly. All subjects at screening will participate in the placebo run-in.
Drug: Rosuvastatin
Subject will receive statin therapy daily
Active Comparator: Arm 15
Dose 15 of statin therapy orally/daily and evolocumab (AMG 145) subcutaneously every 2 weeks
Biological: evolocumab (AMG 145)
Subject will receive evolocumab (AMG 145) every 2 weeks or monthly
Drug: Rosuvastatin
Subject will receive statin therapy daily
Active Comparator: Arm 16
Dose 16 of statin therapy orally/daily and evolocumab (AMG 145) subcutaneously monthly
Biological: evolocumab (AMG 145)
Subject will receive evolocumab (AMG 145) every 2 weeks or monthly
Drug: Rosuvastatin
Subject will receive statin therapy daily
Placebo Comparator: Arm 17
Dose 17 of statin therapy orally/daily and placebo subcutaneously every 2 weeks.
Other: Placebo (administered subcutaneously)
Subject will receive Placebo every 2 weeks or monthly. All subjects at screening will participate in the placebo run-in.
Drug: Rosuvastatin
Subject will receive statin therapy daily
Placebo Comparator: Arm 18
Dose 18 of statin therapy orally/daily and placebo subcutaneously monthly
Other: Placebo (administered subcutaneously)
Subject will receive Placebo every 2 weeks or monthly. All subjects at screening will participate in the placebo run-in.
Drug: Rosuvastatin
Subject will receive statin therapy daily
Active Comparator: Arm 19
Dose 19 of statin therapy orally/daily and evolocumab (AMG 145) subcutaneously every 2 weeks
Biological: evolocumab (AMG 145)
Subject will receive evolocumab (AMG 145) every 2 weeks or monthly
Drug: Rosuvastatin
Subject will receive statin therapy daily
Active Comparator: Arm 20
Dose 20 of statin therapy orally/daily and evolocumab (AMG 145) subcutaneously monthly
Biological: evolocumab (AMG 145)
Subject will receive evolocumab (AMG 145) every 2 weeks or monthly
Drug: Rosuvastatin
Subject will receive statin therapy daily
Placebo Comparator: Arm 21
Dose 21 of statin therapy orally/daily and placebo subcutaneously every 2 weeks
Other: Placebo (administered subcutaneously)
Subject will receive Placebo every 2 weeks or monthly. All subjects at screening will participate in the placebo run-in.
Drug: Simvastatin
Subject will receive statin therapy daily
Placebo Comparator: Arm 22
Dose 22 of statin therapy orally/daily and placebo subcutaneously monthly
Other: Placebo (administered subcutaneously)
Subject will receive Placebo every 2 weeks or monthly. All subjects at screening will participate in the placebo run-in.
Drug: Simvastatin
Subject will receive statin therapy daily
Active Comparator: Arm 23
Dose 23 of statin therapy orally/daily and evolocumab (AMG 145) subcutaneously every 2 weeks
Biological: evolocumab (AMG 145)
Subject will receive evolocumab (AMG 145) every 2 weeks or monthly
Drug: Simvastatin
Subject will receive statin therapy daily
Active Comparator: Arm 24
Dose 24 of statin therapy orally/daily and evolocumab (AMG 145) subcutaneously monthly
Biological: evolocumab (AMG 145)
Subject will receive evolocumab (AMG 145) every 2 weeks or monthly
Drug: Simvastatin
Subject will receive statin therapy daily

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female ≥ 18 to ≤ 80 years of age
  • Subjects not taking a statin with fasting LDL-C of at least 150 mg/dL(4.0 mmol/L)
  • Subjects already on a non-intensive statin with fasting LDL-C at screening of ≥ 100 mg/dL (2.6 mmol/L)
  • Subjects already on a intensive statin with fasting LDL-C at screening of ≥ 80 mg/dL (2.1 mmol/L)
  • Fasting triglycerides ≤ 400 mg/dL (4.5 mmol/L)

Exclusion Criteria:

  • Statin intolerance
  • NYHA III or IV heart failure
  • Uncontrolled hypertension
  • Uncontrolled cardiac arrhythmia
  • Type 1 diabetes, poorly controlled type 2 diabetes
  • Uncontrolled hypothyroidism or hyperthyroidism
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01763866

  Hide Study Locations
Locations
United States, Alabama
Research Site
Birmingham, Alabama, United States, 35294
United States, Arizona
Research Site
Glendale, Arizona, United States, 85306
Research Site
Tucson, Arizona, United States, 85710
Research Site
Tucson, Arizona, United States, 85712
United States, California
Research Site
Carmichael, California, United States, 95608
Research Site
Encino, California, United States, 91436
Research Site
Long Beach, California, United States, 90822
Research Site
Newport Beach, California, United States, 92663
Research Site
San Diego, California, United States, 92123
Research Site
Santa Ana, California, United States, 92705
Research Site
Santa Rosa, California, United States, 95405
Research Site
Thousand Oaks, California, United States, 91360
Research Site
Torrance, California, United States, 90509
Research Site
Tustin, California, United States, 92780
Research Site
Westlake Village, California, United States, 91361
United States, Colorado
Research Site
Littleton, Colorado, United States, 80120
United States, Florida
Research Site
Daytona Beach, Florida, United States, 32117
Research Site
Jacksonville, Florida, United States, 32223
Research Site
Melbourne, Florida, United States, 32901
Research Site
Miami, Florida, United States, 33173
Research Site
Port Charlotte, Florida, United States, 33952
United States, Georgia
Research Site
Atlanta, Georgia, United States, 30342
Research Site
Atlanta, Georgia, United States, 30328
United States, Idaho
Research Site
Boise, Idaho, United States, 83704
United States, Indiana
Research Site
Hammond, Indiana, United States, 46320
Research Site
Indianapolis, Indiana, United States, 46237
Research Site
Valparaiso, Indiana, United States, 46383
United States, Iowa
Research Site
Iowa City, Iowa, United States, 52242
United States, Kentucky
Research Site
Crestview Hills, Kentucky, United States, 41017
United States, Louisiana
Research Site
Monroe, Louisiana, United States, 71203
United States, Maine
Research Site
Auburn, Maine, United States, 04210
Research Site
Bangor, Maine, United States, 04401
Research Site
Portland, Maine, United States, 04101
United States, Maryland
Research Site
Baltimore, Maryland, United States, 21201
United States, Michigan
Research Site
Ypsilanti, Michigan, United States, 48197
United States, Mississippi
Research Site
Tupelo, Mississippi, United States, 38801
United States, Montana
Research Site
Billings, Montana, United States, 59102
United States, New Jersey
Research Site
Voorhees, New Jersey, United States, 08043
United States, New York
Research Site
Manlius, New York, United States, 13104
Research Site
Rochester, New York, United States, 14609
Research Site
Syracuse, New York, United States, 13210
Research Site
Williamsville, New York, United States, 14221
United States, North Carolina
Research Site
Winston-Salem, North Carolina, United States, 27103
United States, Ohio
Research Site
Cadiz, Ohio, United States, 43907
Research Site
Canton, Ohio, United States, 44708
Research Site
Cincinnati, Ohio, United States, 45219
Research Site
Cincinnati, Ohio, United States, 45227
Research Site
Dayton, Ohio, United States, 45414
Research Site
Mansfield, Ohio, United States, 44906
Research Site
Marion, Ohio, United States, 43302
Research Site
Sandusky, Ohio, United States, 44870
United States, Oklahoma
Research Site
Norman, Oklahoma, United States, 73069
United States, Pennsylvania
Research Site
Duncansville, Pennsylvania, United States, 16635
Research Site
Pittsburgh, Pennsylvania, United States, 15216
Research Site
York, Pennsylvania, United States, 17405
United States, South Carolina
Research Site
Florence, South Carolina, United States, 29501
United States, South Dakota
Research Site
Rapid City, South Dakota, United States, 57701
United States, Tennessee
Research Site
Jackson, Tennessee, United States, 38305
Research Site
Jackson, Tennessee, United States, 38301
United States, Texas
Research Site
Dallas, Texas, United States, 75231
Research Site
Houston, Texas, United States, 77074
Research Site
San Antonio, Texas, United States, 78229
United States, Virginia
Research Site
Suffolk, Virginia, United States, 23435
Research Site
Winchester, Virginia, United States, 22601
United States, Washington
Research Site
Tacoma, Washington, United States, 98405
Australia, New South Wales
Research Site
Sydney, New South Wales, Australia, 2022
Australia, South Australia
Research Site
Ashford, South Australia, Australia, 5035
Research Site
Fullarton, South Australia, Australia, 5063
Australia, Victoria
Research Site
Fitzroy, Victoria, Australia, 3065
Research Site
Heidelberg Heights, Victoria, Australia, 3081
Research Site
Richmond, Victoria, Australia, 3121
Belgium
Research Site
Blankenberge, Belgium, 8370
Research Site
Chênée, Belgium, 4032
Research Site
Hasselt, Belgium, 3500
Research Site
Oostende, Belgium, 8400
Research Site
Tremelo, Belgium, 3120
Research Site
Vilvoorde, Belgium, 1800
Canada, British Columbia
Research Site
Burnaby, British Columbia, Canada, V5G 1T4
Research Site
Kelowna, British Columbia, Canada, V1Y 1E4
Research Site
Kelowna, British Columbia, Canada, V1Y 1V6
Research Site
Surrey, British Columbia, Canada, V3V 1N1
Canada, Newfoundland and Labrador
Research Site
St. John’s, Newfoundland and Labrador, Canada, A1A 3R5
Canada, Ontario
Research Site
Cambridge, Ontario, Canada, N1R 6V6
Research Site
Hamilton, Ontario, Canada, L8L 2X2
Research Site
London, Ontario, Canada, N5W 6A2
Research Site
Newmarket, Ontario, Canada, L3Y 5G8
Research Site
Oshawa, Ontario, Canada, L1J 2K1
Research Site
Sarnia, Ontario, Canada, N7T 4X3
Research Site
Scarborough, Ontario, Canada, M1P 2T7
Research Site
Toronto, Ontario, Canada, M8V 3X8
Research Site
Toronto, Ontario, Canada, M9V 4B4
Research Site
Woodstock, Ontario, Canada, N4S 5P5
Canada, Quebec
Research Site
Brossard, Quebec, Canada, J4X 1S4
Research Site
Greenfield Park, Quebec, Canada, J4V 2G8
Research Site
Lachine, Quebec, Canada, H8S 2E4
Research Site
Longueuil, Quebec, Canada, J4N 0C9
Research Site
Montreal, Quebec, Canada, H4N 2W2
Research Site
Pointe-Claire, Quebec, Canada, H9R 3J1
Czech Republic
Research Site
Brno, Czech Republic, 602 00
Research Site
Brno, Czech Republic, 603 00
Research Site
Kladno, Czech Republic, 272 01
Research Site
Litomerice, Czech Republic, 412 01
Research Site
Moravske Budejovice, Czech Republic, 676 02
Research Site
Olomouc, Czech Republic, 775 20
Research Site
Pardubice, Czech Republic, 530 02
Research Site
Praha 2, Czech Republic, 120 00
Research Site
Praha 3, Czech Republic, 130 00
Research Site
Praha 4, Czech Republic, 140 21
Research Site
Slany, Czech Republic, 274 01
Research Site
Svitavy, Czech Republic, 568 25
Research Site
Usti nad Orlici, Czech Republic, 562 18
Denmark
Research Site
Aalborg, Denmark, 9000
Research Site
Ballerup, Denmark, 2750
Research Site
Vejle, Denmark, 7100
France
Research Site
Brest Cedex 2, France, 29200
Research Site
Caen Cedex 9, France, 14033
Research Site
Dijon, France, 21034
Research Site
Le Creusot, France, 71200
Research Site
Montpellier cedex 05, France, 34295
Research Site
Nantes Cedex 1, France, 44093
Research Site
Paris, France, 75013
Research Site
Paris cedex 12, France, 75571
Research Site
Poitiers, France, 86000
Research Site
Strasbourg, France, 67091
Germany
Research Site
Bad Krozingen, Germany, 79189
Research Site
Berlin, Germany, 10787
Research Site
Berlin, Germany, 10367
Research Site
Berlin (Hellersdorf), Germany, 12627
Research Site
Freiburg, Germany, 79106
Research Site
Heidelberg, Germany, 69120
Research Site
Homburg, Germany, 66421
Research Site
Leipzig, Germany, 04103
Research Site
Magdeburg, Germany, 39104
Research Site
Messkirch, Germany, 88605
Research Site
Witten, Germany, 58455
Hong Kong
Research Site
Hong Kong, Hong Kong
Research Site
New Territories, Hong Kong
Hungary
Research Site
Baja, Hungary, 6500
Research Site
Berettyoujfalu, Hungary, 4100
Research Site
Dunaujvaros, Hungary, 2400
Research Site
Eger, Hungary, 3300
Research Site
Gyongyos, Hungary, 3200
Research Site
Hodmezovasarhely, Hungary, 6800
Research Site
Jaszbereny, Hungary, 5100
Research Site
Komarom, Hungary, 2921
Research Site
Marcali, Hungary, 8700
Research Site
Mosonmagyarovar, Hungary, 9200
Research Site
Pecs, Hungary, 7624
Italy
Research Site
Bologna, Italy, 40138
Research Site
Cagliari, Italy, 09134
Research Site
Chieti, Italy, 66100
Research Site
Ferrara, Italy, 44124
Research Site
Milano, Italy, 20162
Research Site
Napoli, Italy, 80131
Research Site
Padova, Italy, 35128
Research Site
Perugia, Italy, 06129
Research Site
Pisa, Italy, 56124
Research Site
Trieste, Italy, 34149
Korea, Republic of
Research Site
Seoul, Korea, Republic of, 120-752
Research Site
Seoul, Korea, Republic of, 135-710
Research Site
Seoul, Korea, Republic of, 138-736
Research Site
Suwon, Korea, Republic of, 443-721
Research Site
Suwon-si, Korea, Republic of, 443-380
Mexico
Research Site
Mexico, Distrito Federal, Mexico, 14000
Research Site
Mexico, Distrito Federal, Mexico, 03800
Research Site
Leon, Guanajuato, Mexico, 37520
Research Site
Guadalajara, Jalisco, Mexico, 44130
Research Site
Guadalajara, Jalisco, Mexico, 44100
Research Site
Monterrey, Nuevo León, Mexico, 64460
Research Site
San Luis Potosi, San Luis PotosÃ-, Mexico, 78240
Research Site
Tampico, Tamaulipas, Mexico, 89000
Research Site
Durango, Mexico, 34270
Netherlands
Research Site
Amsterdam, Netherlands, 1105 AZ
Research Site
Amsterdam, Netherlands, 1066 EC
Research Site
Den Helder, Netherlands, 1782 GZ
Research Site
Groningen, Netherlands, 9728 NT
Research Site
Hoogeveen, Netherlands, 7909 AA
Research Site
Nieuwegein, Netherlands, 3435 CM
Research Site
Nijmegen, Netherlands, 6525 GA
Research Site
Rotterdam, Netherlands, 3045 PM
Research Site
Waalwijk, Netherlands, 5141 BM
Research Site
Zwijndrecht, Netherlands, 3331 LZ
Russian Federation
Research Site
Barnaul, Russian Federation, 656055
Research Site
Kemerovo, Russian Federation, 650002
Research Site
Moscow, Russian Federation, 121552
Research Site
Moscow, Russian Federation, 127299
Research Site
Moscow, Russian Federation, 121002
Research Site
Novosibirsk, Russian Federation, 630047
Research Site
Saint Petersburg, Russian Federation, 197022
Research Site
Saint Petersburg, Russian Federation, 192242
Research Site
Saint Petersburg, Russian Federation, 197341
Research Site
Saint-Petersburg, Russian Federation, 194156
Research Site
Saratov, Russian Federation, 410054
South Africa
Research Site
Alberton, Gauteng, South Africa, 1449
Research Site
Johannesburg, Gauteng, South Africa, 2196
Research Site
Lyttelton, Gauteng, South Africa, 0140
Research Site
Pretoria, Gauteng, South Africa, 0184
Research Site
Kuils River, Western Cape, South Africa, 7580
Research Site
Somerset West, Western Cape, South Africa, 7130
Research Site
Bloemfontein, South Africa, 9301
Research Site
Cape Town, South Africa, 7405
Spain
Research Site
Almeria, AndalucÃ-a, Spain, 04001
Research Site
AlmerÃ-a, AndalucÃ-a, Spain, 04001
Research Site
Barcelona, Cataluña, Spain, 08036
Research Site
Barcelona, Cataluña, Spain, 08003
Research Site
L'Hospitalet de Llobregat, Cataluña, Spain, 08907
Research Site
Valencia, Comunidad Valenciana, Spain, 46010
Research Site
Pozuelo de Alarcon, Madrid, Spain, 28223
Research Site
Pozuelo de Alarcón, Madrid, Spain, 28223
Research Site
Madrid, Spain, 28029
Research Site
Madrid, Spain, 28007
Sweden
Research Site
Göteborg, Sweden, 413 45
Research Site
Lund, Sweden, 222 21
Research Site
Lund, Sweden, 222 22
Research Site
Stockholm, Sweden, 171 45
Research Site
Uddevalla, Sweden, 451 50
Research Site
Ã-rebro, Sweden, 701 46
Switzerland
Research Site
Bellinzona, Switzerland, 6500
Research Site
Geneva 14, Switzerland, 1211
Research Site
Lausanne, Switzerland, 1011
Research Site
Muensterlingen, Switzerland, 8596
Research Site
St. Gallen, Switzerland, 9007
Research Site
Zurich, Switzerland, 8063
Taiwan
Research Site
Kaohsiung, Taiwan, 807
Research Site
Kaohsiung, Taiwan, 83301
Research Site
Taipei, Taiwan, 100
United Kingdom
Research Site
Birmingham, United Kingdom, B15 2SQ
Research Site
Blackpool, United Kingdom, FY3 7EN
Research Site
Cardiff, United Kingdom, CF14 5GJ
Research Site
Chesterfield, United Kingdom, S40 4TF
Research Site
Chorley, United Kingdom, PR7 7NA
Research Site
Doncaster, United Kingdom, DN9 1EP
Research Site
Glasgow, United Kingdom, G45 9AW
Research Site
Glasgow, United Kingdom, G20 0SP
Research Site
Harrow, United Kingdom, HA3 7LT
Research Site
Liverpool, United Kingdom, L22 0LG
Research Site
Liverpool, United Kingdom, L7 8XP
Research Site
Manchester, United Kingdom, M13 9WL
Research Site
Manchester, United Kingdom, M15 6SX
Research Site
Reading, United Kingdom, RG2 0TG
Research Site
Reading, United Kingdom, RG2 0FT
Research Site
Scunthorpe, United Kingdom, DN15 7BH
Research Site
Wakefield, United Kingdom, WF1 4DG
Research Site
Whitby, United Kingdom, YO21 1SD
Sponsors and Collaborators
Amgen
Investigators
Study Director: MD Amgen
  More Information

Additional Information:
No publications provided by Amgen

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Amgen
ClinicalTrials.gov Identifier: NCT01763866     History of Changes
Other Study ID Numbers: 20110115
Study First Received: January 7, 2013
Last Updated: July 8, 2014
Health Authority: Hong Kong: Department of Health
Czech Republic: State Institute for Drug Control
Russia: Ministry of Health of the Russian Federation
Australia: Department of Health and Ageing Therapeutic Goods Administration
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Germany: Paul-Ehrlich-Institut
Spain: Agencia Española de Medicamentos y Productos Sanitarios
Belgium: Federal Agency for Medicinal Products and Health Products
Denmark: Danish Health and Medicines Authority
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Sweden: Medical Products Agency
Switzerland: Swissmedic
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Canada: Health Canada
United States: Food and Drug Administration
Hungary: National Institute of Pharmacy
Italy: Ethics Committee

Keywords provided by Amgen:
High cholesterol, Treatment for high cholesterol, Lowering cholesterol, Lowering high cholesterol, Hypercholesterolemia

Additional relevant MeSH terms:
Hypercholesterolemia
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases
Atorvastatin
Ezetimibe
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Rosuvastatin
Anticholesteremic Agents
Antimetabolites
Enzyme Inhibitors
Hypolipidemic Agents
Lipid Regulating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on November 25, 2014